Cullinan Therapeutics, Inc. CGEM Free cash flow
Discontinued — last reported Q4 '25
Free cash flow at other companies
Other financials
Where this comes from
Calculated from Cullinan Therapeutics, Inc.’s reported figures.
The official record: Cullinan Therapeutics, Inc.’s 10-K, filed March 10, 2026, on SEC EDGAR. View the filing →
Ask your AI about Cullinan Therapeutics, Inc.'s free cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Cullinan Therapeutics, Inc.'s free cash flow?
- Cullinan Therapeutics, Inc. (CGEM) reported free cash flow of -$38.12M in Q4 2025.
- How has Cullinan Therapeutics, Inc.'s free cash flow changed year-over-year?
- Cullinan Therapeutics, Inc.'s free cash flow decreased by 4.1% year-over-year, from -$36.63M to -$38.12M.
- What is the long-term trend for Cullinan Therapeutics, Inc.'s free cash flow?
- Over 2 years (2022 to 2024), Cullinan Therapeutics, Inc.'s free cash flow has grown at a 6.6% compound annual growth rate (CAGR), from -$127.8M to -$145.3M.
- What does free cash flow mean?
- Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.